Company Prepares for Re-Entrance Into Medical Marijuana Sector
HONG KONG / ACCESSWIRE / September 6, 2017 / Lotus Bio-Technology Development Corp. (OTC PINK: LBTD) ("the Company") is pleased to announce it will be undertaking previously announced investments into CBD and Medical Cannabis product development.
In November of 2016 the Company issued a press release detailing its intentions of developing a CBD product line. The subsequent resignation of the Company's former CEO in February of 2017 initially stalled those initiatives. With much of the previous pipeline still in place, as well as stronger partnerships secured, the company is ready to move forward aggressively to develop world class CBD based products for the growing Medical Marijuana sector.
The Company's strategic Chinese partnerships, such as Hunan Cangshi, a successful proprietor, developer, and producer of consumer related organic products, Phyto Nutraceutical Inc., a developer, manufacturer, exporter, and primary supplier of plant extracts and Changsha Huakang Biotechnology Development Co., Ltd, which specializes in extracting active ingredients of natural herbs and plants, places Lotus Bio-Tech in unique position to procure and develop high quality products and compete for significant market share in the Cannabis Industry.
The company will also be seeking U.S.-based strategic partnerships to help facilitate with its end user supply chain for new products as well as to explore additional opportunities within the Medical Marijuana space.
News 
Market Data 
Discover 
AI
